Recall Register

Food, drugs, devices › Instrumentation Laboratory

Device recall: HemosIL ReadiPlasTin, Part No. 0020301400

FDA enforcement event 90012 · Class II · initiated 8 Apr 2022 · status Ongoing

DeviceVoluntary: Firm initiated1 product recordBedford, MA

FDA enforcement event 90012 is a device recall by Instrumentation Laboratory of Bedford, MA, initiated 8 Apr 2022 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 88% of the 839 device enforcement events initiated in 2022 carry the same class.

Status: Ongoing. Initiation: voluntary: firm initiated. Instrumentation Laboratory has 14 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Instrumentation Laboratory, Bedford, MA.

Reason for recall

"Variable and out of specification QC results with HemosIL ReadiPlasTin. IL will remove all lots from the market and convert customers to an alternative prothrombin time (PT) reagent, specifically HemosIL RecombiPlasTin 2G."

Distribution

"US Nationwide distribution including in the states of AZ, CA, IA, IL, IN, KS, MD, ME, MI, MN, MO, NC, NE, NY, OH, OK, SC, TX, VA, WV."

Product records

Recall numberProductQuantityClassStatusReport date
Z-1052-2022HemosIL ReadiPlasTin, Part No. 00203014001,563 (US); 29,046 (OUS)Class IIOngoing18 May 2022

Context

88%of 2022 device events are Class II839 events that year
1product record in this eventfirm median: 1
14events on this register for the firm

Other enforcement events for Instrumentation Laboratory

InitiatedProduct (first record)TypeClassRecords
21 May 2026GEM Premier 7000 with iQM3 Part Numbers: 00077407508 00077407510 00077415004 00077415008 00077415010 00077430010 ProductDeviceClass II2
8 May 2026GEM Premier 5000 with IQM2 Model/Catalog Number: 00024019255 and GEM Premier 7000 with iQM3 Model/Catalog Number: 000000DeviceClass II6
20 Jan 2026GEM Premier 5000 PAK, Part No. 00055360004.DeviceClass II20
11 Dec 2025The product is used for the evaluation of the intrinsic coagulation pathway, APTT substitution test and the monitoring oDeviceClass II1
18 Nov 2025HemosIL SynthAFax. Partial Thromboplastin Time Tests.DeviceClass III1
3 Feb 2025HemosIL LMW Heparin Controls; Part Number: 0020300200;DeviceClass II1
18 Dec 2024HemosIL Heparin Calibrators; Part Number: 0020300600; in vitro diagnosticDeviceClass II1
29 Sep 2023GEM Premier 3000 PAK - pH, pCO2, pO2, Hct, Part Numbers 00024307504, 00024330004, 00024345004DeviceClass II3
13 Jul 2023ACL TOP Family 50 Series Models as follows: In vitro diagnostic clinical use in the hemostasis laboratory for coagulatioDeviceClass II1
3 Feb 2023ACL ELITE- Analyzer designed specifically for clinical use in the hemostasis laboratory, for coagulation and/or fibrinolDeviceClass II4

All 14 events for Instrumentation Laboratory

Questions and answers

Why was this device recalled?

FDA's record gives the reason for recall as: "Variable and out of specification QC results with HemosIL ReadiPlasTin. IL will remove all lots from the market and convert customers to an alternative prothrombin time (PT) reagent, specifically HemosIL RecombiPlasTin 2G."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "US Nationwide distribution including in the states of AZ, CA, IA, IL, IN, KS, MD, ME, MI, MN, MO, NC, NE, NY, OH, OK, SC, TX, VA, WV."

Is the recall still ongoing?

FDA lists the status as Ongoing. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA device enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.